The litigation centers on claims that ADMA Biologics issued materially false or misleading statements throughout the specified period. According to the complaint, the company allegedly failed to disclose an undisclosed related party transaction and utilized channel stuffing to artificially inflate its revenue figures. Furthermore, the lawsuit asserts that the firm lacked adequate internal controls, rendering its public statements about business operations and financial prospects baseless.

Shareholders who acquired stock during this window are eligible to join the action without incurring out-of-pocket costs, as the case is being handled on a contingency fee basis. While investors may choose to remain absent members of the class, those interested in directing the litigation as a lead plaintiff must petition the court by the August deadline. No class has been certified yet, meaning investors are currently responsible for retaining their own counsel if they wish to be represented.